Clinical trials: Locally Advanced Basal Cell Carcinoma
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Basal Cell
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic…
- Trial name
- NCT03897036
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Senhwa Biosciences, Inc.
Basal Cell Carcinoma, Radiotherapy; Complications
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy.
- Trial name
- RADIOSONIC (NCT05561634)
- Testing
- Radiotherapy, Observation, Vismodegib
- Where
- France
- Volunteers
- 82 people
- Sponsor
- University Hospital, Lille
Basal Cell Carcinoma
An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants
This multi-center, observational study involves reviewing the medical records of approximately 100 adult participants diagnosed with advanced BCC from 01 January 2005 until 31 December 2010.
- Trial name
- NCT02100111
- Where
- 42 sites in France, Germany and 2 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
- Trial name
- NCT02354261
- Testing
- SUBA-Itraconazole
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- HedgePath Pharmaceuticals, Inc.
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients.
- Conditions
- Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome
- Trial name
- NCT05463757
- Testing
- Vismodegib, Sonidegib
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Basal Cell Carcinoma
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma.
- Trial name
- NCT01367665
- Testing
- vismodegib
- Where
- 181 sites in Argentina, Australia and 35 more
- Volunteers
- 1,232 people
- Sponsor
- Hoffmann-La Roche
Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
This phase II trial studies how well enzalutamide works in treating patients with androgen receptor positive salivary cancers that have spread from where it started to nearby tissue or lymph nodes (locally advanced) or have…
- Conditions
- Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma
- Trial name
- NCT02749903
- Testing
- enzalutamide
- Where
- 287 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-melanoma Skin Cancer, Basal Cell Carcinoma
T-VEC in Non-melanoma Skin Cancer
Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.
- Conditions
- Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Cutaneous Lymphoma
- Trial name
- 20139157 T-VEC (NCT03458117)
- Testing
- Talimogene Laherparepvec (T-VEC)
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- University of Zurich
Locally Advanced Basal Cell Carcinoma, Skin Cancer
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and…
- Conditions
- Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
- Trial name
- NCT01835626
- Testing
- Vismodegib, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sue Yom
Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
A non-randomized two-cohort study of neoadjuvant Cemiplimab or neoadjuvant Cemiplimab plus Fianlimab (CF) in patients with basal cell carcinoma of the head and neck.
- Trial name
- NCT05929664
- Testing
- Cemiplimab, Computed Tomography, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Thomas Jefferson University
Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1
Vismodegib (ERIVEDGE®) at the standard dose of 150 mg/day orally is indicated for the treatment of advanced Basal Cell Carcinoma (BCC) and is associated with many adverse effects.
- Trial name
- OPTIVISMO-1 (NCT03610022)
- Testing
- Treatment with vismodegib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Bordeaux
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory…
- Trial name
- NCT01160250
- Testing
- vismodegib (GDC-0449)
- Where
- 11 sites in United States
- Sponsor
- Genentech, Inc.
Solid Cancers
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
- Trial name
- NCT00968981
- Testing
- GDC-0449
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Basal Cell Carcinoma
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
This is a prospective single-center, open label, pilot study to investigate the safety and efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.
- Trial name
- NCT01529450
- Testing
- LDE225
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Anne Chang
Basal Cell Carcinoma
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma.
- Trial name
- NCT06344052
- Testing
- SP-002, Vismodegib
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Stamford Pharmaceuticals, Inc.